 WATERTOWN, Mass., July 08, 2021 GLOBE NEWSWIRE -- Selecta Biosciences, Inc. NASDAQ: SELB, a biotechnology company leveraging its clinically validated ImmTORTM platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selectas Chief Executive Officer, Carsten Brunn, Ph.D., will participate in one-on-one investor meetings and Chief Science Officer, Takashi Kei Kishimoto, Ph.D., will participate in a panel discussion at the William Blair Biotech Focus Conference 2021 to be held virtually, July 14-15. 